Skip to main content
. Author manuscript; available in PMC: 2020 Jun 11.
Published in final edited form as: Oncogene. 2019 Dec 11;39(11):2275–2289. doi: 10.1038/s41388-019-1141-7

Figure 4. CD154 neutralization or shRNA knockdown rescues migration but not proliferation of CCR2-deficient carcinoma cells.

Figure 4.

A-C. PyVmT mammary carcinoma cells transfected with Con-si or CCR2-si were analyzed for CCR2 expression by flow cytometry (A), CD154 (B) or CCL2 (C) expression in conditioned medium by ELISA (C). D-E. Control or CCR2-deficient PyVmT cells were treated with or without 1 μg/ml IgG or anti-CD154 neutralizing antibodies, and were analyzed for PCNA expression by immunofluorescence staining (D), or wound closure (E). F-G. PyVmT cells were generated to stably express control shRNAs (Con-sh) or CD154 shRNAs (CD154-sh),and then were transfected with Con-si or CCR2-si. Cells were analyzed for expression of CD154 and CCR2 by immunoblot (F) or changes in wound closure (G). PCNA staining was quantified by Image J. Expression was normalized to DAPI, arbitrary units are shown. Statistical significance was determined by p<0.05. *p<0.05, ns=not significant. Mean±SEM are shown.